

## CURRICULUM VITAE

Amir H. Guerami, M.D.

### Education

2001	B.A.	Georgetown University, Washington D.C. Psychology and Biology
2005	M.D.	University of Maryland School of Medicine Medicine

### Post Graduate Education and Work Experience

07/05 – 06/06	Internship	Mercy Medical Center Baltimore, Maryland
07/06 – 06/09	Ophthalmology Residency	University of Maryland Medical Center Dept. of Ophthalmology & Visual Sciences Baltimore, Maryland
07/09 – 06/10	Vitreoretinal Fellowship	University of British Columbia Vancouver, British Columbia
8/10 – 06/13	Clinical Director Associate Program Director Assistant Professor Director, Retina Service	University of Maryland Medical Center Dept. of Ophthalmology & Visual Sciences Baltimore, Maryland
07/13 – present	Associate	Valley Retina Medical Associates / The Retina Partners

### Professional Society Memberships

2012-present	Board Certified, American Board of Ophthalmology
2012-present	Member, American Society of Retinal Specialists
2006-present	Member, American Academy of Ophthalmology
2006-2009	Member, American Society of Cataract and Refractive Surgery/ASOA
2001-present	Member, American Medical Association
2005-present	Member, Rush Medical Society

## **Honors and Awards**

- 07/08 – 06/09 Chief Resident, Department of Ophthalmology & Visual Sciences  
University of Maryland School of Medicine
- 2005 Cum Laude, Georgetown University

## **Research Experience**

- 2009-2010 QLT Inc. Protocol Number: BPD OCR (RADICAL)  
A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence-Visudyne-Lucentis Combination Therapies and Lucentis Monotherapy in Subjects with CNV Secondary to AMD
- 2009-2010 Regeneron Pharmaceuticals, Inc. Protocol Number: VGFT-OD-0605.01 –  
A Randomized, Double-Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration
- 2009- 2010 Regeneron Pharmaceuticals, Inc. Protocol Number: VGFT-OD-0819 –  
A Randomized, Double-Masked, Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
- 2013-present Thrombogenics. Ocriplasmin Research to Better Inform Treatment (ORBIT). This is a multicenter, prospective, observational, Phase 4 study that will assess clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA).

## **Publications**

Hertle RW, Maybodi M, Reed GF, **Gueramí AH**, Yang D, Fitzgibbon, EJ. Latency of dynamic and gaze-dependent optotype recognition in patients with infantile nystagmus syndrome versus control subjects. Ann N Y Acad Sci. 2002 Apr;95:601-603.

## **Lectures and Presentations**

- 2000 Latency of Dynamic and Gaze-Dependent Optotype Recognition in Patients with Infantile Nystagmus Syndrome versus Control Subjects.

Association for Research in Vision and Ophthalmology (ARVO)  
Lecture presentation.

- 2007            Iatrogenic Horner Syndrome Diagnosed with 0.5% Apraclonidine.  
                  NANOS  
                  Poster presentation.
- 2009            Cavernous Sinus Extension of Orbital Foreign Body: A Case Report.  
                  NANOS  
                  Poster presentation.
- 2010            Guest Speaker  
                  British Columbia Society of Eye Physicians and Surgeons  
                  Retina and Ocular Trauma Day, April 30, 2010
- 2011            Guest Panelist  
                  Maryland Society of Eye Physicians & Surgeons  
                  May 20, 2011
- 2012            Case presentation, Macula 2012 Conference  
                  New York, NY  
                  January 18, 2012

**Professional Licenses**

California    A124952

**Languages**

English and Farsi (fluent)